ONCO
HEALTHCAREOnconetix Inc
Live · NASDAQ · May 9, Close
What's Moving ONCO Today?
No stock-specific AI insight has been generated for ONCO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.45
Fundamentals
Trading
ONCO News
21 articles- Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and DevelopmentYahoo Finance·Apr 17, 2026
- Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to EricssonYahoo Finance·Apr 9, 2026
- Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I StrategyYahoo Finance·Apr 7, 2026
- Onconetix Highlights Realbotix AI Humanoid Robot Delivery UpdateYahoo Finance·Apr 2, 2026
- Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of DirectorsYahoo Finance·Mar 31, 2026
- BC-Most Active StocksYahoo Finance·Mar 27, 2026
- What's Going On With Onconetix Shares On Friday?Benzinga·Mar 27, 2026
- Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial DemonstrationYahoo Finance·Mar 25, 2026
- Onconetix, Inc. Announces 1-for-5 Reverse Stock SplitYahoo Finance·Mar 23, 2026
- Realbotix Announces the Sale of Realbotix, LLC Subsidiary to OnconetixYahoo Finance·Feb 12, 2026
- Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed IssuerYahoo Finance·Feb 12, 2026
- Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics CompanyYahoo Finance·Feb 12, 2026
- Onconetix announces financing through private placement, debt settlementYahoo Finance·Sep 27, 2025
- Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.Yahoo Finance·Sep 26, 2025
- Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger AgreementYahoo Finance·Sep 26, 2025
- Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTMYahoo Finance·Sep 22, 2025
- Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreementYahoo Finance·Jul 16, 2025
- Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings PanelYahoo Finance·Jun 16, 2025
- Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of StockholdersYahoo Finance·Jun 11, 2025
- Onconetix receives additional delisting notice from NasdaqYahoo Finance·May 23, 2025
- Onconetix, Inc. Announces Receipt of Additional Notice from NasdaqYahoo Finance·May 22, 2025
All 21 articles loaded
Price Data
52-Week Range
$0.45
Fundamentals
Trading
About Onconetix Inc
Onconetix Inc. is a leading biotechnology company at the forefront of revolutionizing cancer care through innovative diagnostic and therapeutic solutions. Utilizing a proprietary technology platform, the firm emphasizes early detection and personalized treatment approaches for a range of malignancies, aiming to fulfill a vital need in oncology. With a strong and diverse pipeline, Onconetix is strategically positioned to address the rising demand for effective cancer therapies, significantly improving patient outcomes through its advanced research and development efforts in the dynamic landscape of cancer treatment.